Filing Flows › Lineage Cell Therapeutics (LCTX) › Next earnings date
Lineage Cell Therapeutics (LCTX) earnings on Nov 12, 2026: what to expect
Lineage Cell Therapeutics (LCTX) is expected to report earnings on Nov 12, 2026, in 4 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.04 (−$0.04 to −$0.03, 4 estimates) on revenue of $2.0M, against −$0.13 and $3.7M a year ago. It beat the EPS estimate in 67% of the quarters on record; Filing Flows' model gives it a 73% chance of beating next time.
What to watch
Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:
Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.13 on revenue of $2.9M, against the analysts' −$0.04.
The last report
Lineage Cell Therapeutics reported revenue of $1.1M for the second quarter 2026 (-61% Y/Y), net earnings $1.5M: Collaboration Revenues $943K, Royalties License and Other Revenues $126K. How it makes money → · Every quarter →
Lineage Cell Therapeutics' latest quarter
Lineage Cell Therapeutics, Q2 2026: revenue $1.1M (-61% year over year), operating margin -834.7%, net earnings $1.5M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Questions
When does LCTX report earnings?
Lineage Cell Therapeutics is expected to report on Nov 12, 2026.
What are analysts expecting from Lineage Cell Therapeutics?
EPS of −$0.04 and revenue of $2.0M for the quarter.
Does Lineage Cell Therapeutics usually beat earnings?
It beat the consensus EPS estimate in 67% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.